References
Zidar N, Langner C, Jerala M, Boštjančič E, Drobne D, Tomažič A. Pathology of fibrosis in Crohn’s disease-contribution to understanding its pathogenesis. Front Med (Lausanne). 2020;7:167.
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.
Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.
Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.
Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a (68)Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60:1743–9.
Schmidkonz C, Rauber S, Atzinger A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485–91.
Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein targeted PET/CT with (68)Ga-FAPI for imaging IgG4-related disease: comparison to (18)F-FDG PET/CT. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.244723.
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783–803.
Acknowledgments
This work is supported by the CAMS Initiative for Innovative Medicine (CAMS-I2M, 2017-I2M-3-001).
Funding
This work was supported by the CAMS Initiative for Innovative Medicine (CAMS-I2M, 2017-I2M-3-001).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the institutional review board of our hospital and registered at Clinicaltrial.gov (NCT04507932). Written informed consent for publication of this report was obtained from the patient. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Image of the month.
Rights and permissions
About this article
Cite this article
Luo, Y., Pan, Q., Xu, H. et al. Active uptake of 68Ga-FAPI in Crohn’s disease but not in ulcerative colitis. Eur J Nucl Med Mol Imaging 48, 1682–1683 (2021). https://doi.org/10.1007/s00259-020-05129-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-020-05129-7